Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17646469 | 0.98 | ADRA2C (0.53) | ADRA2CTAAR1DRD2DRD1GLA | |
| Hydrochloric Acid SCHEMBL29678214 | 0.98 | ADRA2C (0.53) | ADRA2CTAAR1DRD2DRD1GLA | |
| SCHEMBL6420561 | 0.89 | ADRA2C (0.47) | ADRA2CGLALOXL2CYP2A6HTR6 | |
| SCHEMBL2154019 | 0.87 | GLA (0.53) | GLAMEN1KMT2ACYP19A1CYP11B1 | |
| Trifluoroacetic Acid SCHEMBL3750230 | 0.84 | FFAR1 (0.49) | ADRA2CTAAR1DRD2DRD1KIF11 | |
| SCHEMBL27986680 | 0.84 | GLA (0.47) | ADRA2CGLALOXL2MEN1KMT2A | |
| SCHEMBL28248372 | 0.83 | HTR2B (0.54) | DRD2GLAMEN1KMT2ACYP19A1 | |
| SCHEMBL28865565 | 0.83 | HTR2B (0.50) | DRD2GLAMEN1KMT2ACYP19A1 | |
| SCHEMBL580840 | 0.83 | LOXL2 (0.61) | ADRA2CGLALOXL2CYP19A1CYP11B1 | |
| Water SCHEMBL5709133 | 0.83 | LOXL2 (0.61) | ADRA2CGLALOXL2CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-3875458-A1 | DIPHENYL-LIKE COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF | Shanghai Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2021-09-08 | — | — | EP | disclosed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783500-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9663468-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| EP-0907731-B1 | METABOTROPIC GABA(B) RECEPTORS, RECEPTOR-SPECIFIC LIGANDS AND THEIR USES | NOVARTIS AG (CH) | 2005-03-02 | — | — | EP | disclosed |
| EP-1343749-A2 | METHOD FOR PRODUCING PRIMARY AND SECONDARY AMINES BY HYDROGENATING NITRILES AND IMINES | Degussa AG (DE) | 2003-09-17 | — | — | EP | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020091250-A1 | Metabotropic GABA [B] receptors, receptor-specific ligands and their uses | NOVARTIS AG (CH) | 2002-07-11 | — | — | US | disclosed |
| WO-2002051791-A2 | METHOD FOR PRODUCING PRIMARY AND SECONDARY AMINES BY HYDROGENATING NITRILES AND IMINES | DEGUSSA AG (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0907731-A1 | METABOTROPIC GABA(B) RECEPTORS, RECEPTOR-SPECIFIC LIGANDS AND THEIR USES | Novartis AG (CH) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997046675-A1 | METABOTROPIC GABA[B] RECEPTORS, RECEPTOR-SPECIFIC LIGANDS AND THEIR USES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091250-A1 | Metabotropic GABA [B] receptors, receptor-specific ligands and their uses | GABBR1, GABBR2, GABRB1 | ADRA2C 401/4885TAAR1 118/4885DRD2 488/4885 |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | ADRA2C 509/4885TAAR1 2347/4885DRD2 1049/4885 |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | ADRA2C 509/4885TAAR1 2347/4885DRD2 1049/4885 |
| US-20160368877-A1 | 2-Aminoquinoline-Based Compounds for Potent and Selective Neuronal Nitric Oxide Synthase Inhibition | NOS2, NOS3, NOS1 | ADRA2C 376/4885TAAR1 797/4885DRD2 1055/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | ADRA2C 45/4885TAAR1 1932/4885DRD2 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.